A 73-year-old female was transferred to the intensive care unit (ICU) following amputation of the right hallux and second toe, consequent to a persistent requirement for cardiovascular support after surgery. Following induction of anaesthesia, the patient required increasing cardiovascular support in the form of peripheral vasopressors. The operation was otherwise uneventful with no macroscopic signs that the site was infected. Past medical history included antiphospholipid syndrome (APLS) with high titres of antiphospholid antibodies, associated antiprothrombin antibodies, chronic obstructive pulmonary disease, hypertension and peripheral vascular disease. One month prior to this operation she had undergone right popliteal angioplasty that had successfully restored arterial patency but had resulted in distal digital ischaemia requiring amputation.
During the initial 12 hours the patient required noradrenaline, vasopressin and aggressive fluid therapy to maintain a mean arterial pressure of greater than 60 mm Hg. Cardiac output (CO) monitoring using a lithium dilution cardiac output device (LiDCO TM ) demonstrated a high CO, low stoke volume and low systemic vascular resistance which improved with treatment. Initial investigations showed WCC 25.5 × 10 9 /L and CRP 272 mg/L. Tazocin, vancomycin and metronidazole were started empirically for presumed septic shock, with the source thought to be the ischaemic foot. During the first night the patient also developed central chest pain and dyspnoea with an elevated 12-hour troponin I level of 2.14 µg/L (normal range <0.07 µg/L).
Standard coagulation tests revealed an elevated activated partial thromboplastin time ratio (APTR), elevated internationalised ratio (INR), low platelet count and a fibrinogen level within the normal range. These results were similar to the preoperative period, consistent with the underlying APLS and anti-prothrombin antibodies. Thromboelastography was attempted on two occasions but resulted in R times in excess of 60 minutes (normal range 4-8 minutes) and these results were disregarded. Prophylactic heparin was commenced on day one after discussion with a haematologist. On day two, catastrophic antiphospholipid syndrome (CAPS) was considered a possibility and systemic anticoagulation and IV immunoglobulin (IVIG) were started on the advice of the rheumatology specialist. The possibility of ongoing sepsis was felt to preclude the use of high dose steroids.
By day three the patient was more haemodynamically stable on a low dose of noradrenaline. Despite this, the renal function continued to deteriorate and renal replacement therapy was started. There were a number of interruptions due to access difficulties and cessation of heparin and secondary to elevated APTR results. With haematology specialist advice, anti-Xa levels were used to monitor heparin activity aiming for a target of 0.5 to 1.0 IU/mL. Levels on day four were 0.0, rising to 0.46 by day five and 0.56 on day six.
Concerns regarding areas of tissue necrosis around the amputation site and rising inflammatory markers prompted a review by the vascular surgeons. Despite a lack of positive culture results and the wound appearing sterile, the consensus was to proceed to a below knee amputation.
Later that day and prior to surgery the patient suddenly deteriorated, becoming unresponsive with fixed, dilated pupils, hypertension and an irregular breathing pattern consistent with a clinical presentation of a catastrophic intracranial event. Imaging to confirm this was not deemed necessary. Supportive care was discontinued and the patient died shortly afterwards. No post mortem was carried out.
Discussion
CAPS was first described in 1992 1 and the diagnosis and awareness of this life-threatening, accelerated form of the condition has grown since. It represents less than 1% of cases of APLS 2 but has a reported mortality up to 50%. The hallmark finding is of multiple small vessel thromboses rather than the Probable catastrophic antiphospholipid syndrome mimicking severe sepsis after digital amputation R Chambers, K Nolan Antiphospholipid syndrome (APLS) is an autoimmune disorder characterised by veno-arterial thrombosis, adverse outcomes in pregnancy and raised titres of antiphospholipid antibodies. The catastrophic variant is rare and makes up less than 1% of cases but carries a high mortality. We present a case of probable catastrophic antiphospholipid syndrome (CAPS) presenting shortly after toe amputation under general anaesthesia.
Keywords: antiphospholipid syndrome; sepsis; intensive care; amputation; molecular mimicry medium to large vessel occlusions found with classic APLS. In 2003, a consensus statement was produced in an attempt to define CAPS and provide guidance on management. 3 Criteria for diagnosis include multiple organ involvement over a short time period, presence of antiphospholipid antibodies, usually in high titres, and histopathological evidence of small vessel occlusion. In this case, the levels of anticardiolipin were 111.1 U/mL (normal range 0-10 U/mL) and anti-β 2glycoprotein I >100 U/mL (normal range 0-8.2 U/mL), so on the basis of the criteria our patient would be classified as a probable case, as we did not request histological investigation.
The majority of cases have at least one precipitating event, most frequently sepsis but other precipitants include trauma, surgery, oral contraception, anticoagulation withdrawal, immunisation and pregnancy. 4 Multiple triggering factors may be present, often termed the double-or triple-hit theory. In this case, angioplasty one month prior to presentation, followed by withdrawal of anticoagulation, surgical trauma and possible infection may have all contributed.
This presentation of rapid deterioration with micro-vascular thrombosis and multi-organ dysfunction is well recognised in ICU patients and common to many conditions. Possible mechanisms to explain CAPS include a thrombotic storm and a systemic inflammatory response syndrome (SIRS). The thrombotic storm arises from the initial vascular occlusion, which triggers further activation of the clotting system. APLS is associated with increased levels of plasminogen activator inhibitor type 1 and protein C dysfunction. 6 Together, this results in hypofibrinolysis which may explain the extensive thrombosis seen microscopically. 5 This uncontrolled thrombosis leads to a picture similar to disseminated intravascular coagulation (DIC) and in a review of 176 patients on the CAPS registry, 13% had evidence of DIC. 6 Patients with CAPS often have SIRS. Necrotic tissue and damaged endothelium are both potent triggers for cytokine release. CAPS and severe sepsis share many features and infection is one of the common triggers for CAPS. There is some in vitro evidence that antiphospholipid antibodies such as anti-β 2 -glycoprotein I bind to and activate endothelial cells in an identical manner to lipopolysaccharide, activating cytokine gene promoters for IL-1, IL-6 and TNFα. 7 Some bacterial and viral peptides closely resemble portions of β 2 -glycoprotein I and in vitro generate pathogenic antiphospholipid antibodies. 7 This 'molecular mimicry' may explain why infection is such a common trigger for CAPS and why the cellular response may be similar.
In our case, the patient was treated with broad-spectrum antibiotics because the presentation appeared to be of severe sepsis. No organisms were identified despite multiple cultures, and comments were made on two occasions that the surgical site did not appear macroscopically infected. High dose steroids, one of the recognised treatments for CAPS were withheld because of the fear of ongoing infection. This highlights one of the difficulties in treating these patients.
As yet, there are no large randomised trials on which to base treatments for CAPS. One study that looked at mortality in 250 patients on the CAPS registry 2 identified cerebral involvement as the main cause of death, as in this case. Authors identified a reduction in mortality over time from 53% prior to 2001 to 33.3% after. Logistic regression associated the higher use of combined treatment (anticoagulation, corticosteroids, plasma exchange and/or IVIG) with a decrease in mortality rate in the later group. This parallels the guidance in the consensus statement which recommends effective anticoagulation, high dose steroids, IVIG and/or plasma exchange for lifethreatening cases.
This case also highlights the problems faced with standard in vitro tests of coagulation in APLS patients. The prolongation of the phospholipid-dependent assays of coagulation such as the APTR means they are open to misinterpretation. Other antibodies to coagulation factors are also often associated with APLS, such as anti-prothrombin antibodies, potentially resulting in a combined thrombotic and bleeding risk. 8 In this case, the patient had high titres of antiphospholipid and antiprothrombin antibodies which resulted in a prolongation of the APTR and INR. The misinterpretation of the prolonged APTR and INR resulted in interruptions to systemic anticoagulation and renal replacement therapy. The British Haematological Society recommends that anti-Xa levels are used to monitor heparin effect in patients with APLS. 9 In such cases, close liaison with haematology specialists is vital to manage the combined bleeding and thrombotic risk.
